RNAi Therapy Market Dominated by Oncology Focused Drugs

RNA interference is considered to be a turning point for molecular biology.

Release Date: 11-Aug-2014



“Global RNAi Therapy Market Outlook 2018” Report Highlights: 

 

Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts.

There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be “undruggable” by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market.

 

For Report Sample Visit:”Global RNA Interference (RNAi) Therapy Market Outlook 2018”

Or Contact: avainsh@kuickresearch.com

Need custom market research solution? We can help you with that too.